GnRH agonists as contraceptive agents: predicted significantly reduced risk of breast cancer

Contraception. 1991 Sep;44(3):289-310. doi: 10.1016/0010-7824(91)90019-c.

Abstract

Gonadotrophin-releasing hormone agonists (GnRHAs) were investigated as contraceptive agents from the late 1970's to the mid-1980's. They were abandoned as they appeared to offer no advantage over conventional combination-type oral contraceptives (COCs). This conclusion appears to be incorrect. We propose here a contraceptive regimen of a depot formulation of a GnRHA plus add-back estrogen and intermittent progestogen. The dose of add-back sex-steroids is substantially less than that in COCs; this reduction in sex-steroids should lead to a major reduction in lifetime breast cancer occurrence.

Publication types

  • Review

MeSH terms

  • Bone and Bones / metabolism
  • Breast Neoplasms / epidemiology
  • Breast Neoplasms / prevention & control*
  • Contraceptive Agents, Female / adverse effects
  • Contraceptive Agents, Female / pharmacology
  • Endometrial Neoplasms / epidemiology
  • Endometrial Neoplasms / prevention & control
  • Estrogens, Conjugated (USP) / pharmacology
  • Female
  • Gonadotropin-Releasing Hormone / adverse effects
  • Gonadotropin-Releasing Hormone / antagonists & inhibitors*
  • Gonadotropin-Releasing Hormone / pharmacology
  • Humans
  • Leuprolide / pharmacology
  • Lipid Metabolism
  • Liver / metabolism
  • Medroxyprogesterone / analogs & derivatives
  • Medroxyprogesterone / pharmacology
  • Medroxyprogesterone Acetate
  • Ovarian Neoplasms / epidemiology
  • Ovarian Neoplasms / prevention & control
  • Ovary / drug effects
  • Risk Factors

Substances

  • Contraceptive Agents, Female
  • Estrogens, Conjugated (USP)
  • Gonadotropin-Releasing Hormone
  • Medroxyprogesterone Acetate
  • Leuprolide
  • Medroxyprogesterone